Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers

Seminars in Oncology

Volumn 31, Issue SUPPL. 14, 2004, Pages 17-24

  Muggia, Franco M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TOPOTECAN; VINCRISTINE;

ANEMIA; BONE MARROW TOXICITY; CANCER INVASION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; ENDOMETRIUM CANCER; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GYNECOLOGIC CANCER; HUMAN; HYPERSENSITIVITY; HYSTERECTOMY; LYMPHADENECTOMY; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; UTERINE CERVICAL NEOPLASMS;

EID: 11344260692     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.11.007     Document Type: Conference Paper

References (60)

1. American Cancer Society Cancer Facts and Figures 2004 2004 American Cancer Society Atlanta, GA
2. S.A. Cannistra, J.M. Niloff Cancer of the uterine cervix N Engl J Med 334 1996 1030 1038
3. G. Delgado, B. Bundy, R. Zaino Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix A Gynecologic Oncology Group Study Gynecol Oncol 38 1990 352 358
4. U.A. Bianchi, E. Sartori, S. Pecorelli Treatment of primary invasive cervical cancer Considerations on 997 consecutive cases Eur J Gynaecol 9 1988 47 53
5. F. Muggia, S. Formenti, J. Curtin Chemoradiation for patients with cervical cancer J.T. Jr DeVita S. Hellman S.A. Rosenberg Progress in Oncology 2001 2001 Jones and Bartlett Sudbury, MA 168 190
6. R. Yancik Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality Cancer 71 suppl 1993 517 523
7. F.M. Muggia Sequential single agents as first-line chemotherapy for ovarian cancer A strategy derived from the results of GOG-132 Int J Gynecol Cancer 13 suppl 2 2003 156 162
8. C.P. Morrow, B.N. Bundy, H.D. Homesley Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II A Gynecologic Oncology Group Study Gynecol Oncol 36 1990 166 171
9. J.T. Thigpen, J.A. Blessing, H. Ball Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy A Gynecologic Oncology Group study J Clin Oncol 12 1994 1748 1753
10. J.T. Thigpen, M.F. Brady, H.D. Homesley Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinima. A Gynecologic Oncology Group study J Clin Oncol 22 2004 3902 3908
11. G. Fleming, V. Brunetto, R. Bentley Randomized trial of doxorubicin (DOX) plus cisplatin (CIS) versus DOX plus paclitaxel (TAX) plus granulocyte colony-stimulating factor (G-CSF) in patients with advanced or recurrent endometrial cancer A report on Gynecologic Oncology Group (GOG) protocol Proc Am Soc Clin Oncol 19 2000 379 (abstr 1498)
12. G. Fleming, V.L. Brunetto, D. Cella Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma A Gynecologic Oncology Group study J Clin Oncol 22 2004 2159 2166
13. M. Randall, H. Brunetto, R. Muss Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma A randomized phase III trial of the Gynecologic Oncology Group Proc Am Soc Clin Oncol 22 2003 2 (abstr 3)
14. C.M. Morosky, D. O'Malley, J. Tangir Carboplatin/Paclitaxel as adjuvant therapy for stage III endometrial adenocarcinoma Proc Am Soc Clin Oncol 23 2004 465 (abstr 5071)
15. K. Ito, S. Adachi, Y. Itani Phase II trial of weekly paclitaxel and carboplatin (wTJ) for endometrial cancer (EC) Results of a Kansai Clinical Oncology Group trial (KCOG0015) in Japan Proc Am Soc Clin Oncol 23 2004 468 (abstr 5085)
16. H. Watari, Y. Todo, M. Takeda A multivariate analysis on histopathologic prognostic factors for predicting outcome of node-positive endometrial carcinoma Proc Am Soc Clin Oncol 23 2004 463 (abstr 5064)
17. C.W. Whitney, W. Sause, B.N. Bundy Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes A Gynecologic Oncology Group and Southwest Oncology Group study J Clin Oncol 17 1999 1339 1348
18. M. Morris, P.J. Eifel, J. Lu Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer N Engl J Med 340 1999 1137 1143
19. P.G. Rose, B.N. Bundy, E.B. Watkins Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer N Engl J Med 340 1999 1144 1153
20. H.M. Keys, B.N. Bundy, F.B. Stehman Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma N Engl J Med 340 1999 1154 1161
21. W.A. Peters III, P.Y. Liu, R.J. Barrett Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix J Clin Oncol 18 2000 1606 1613
22. N. Colombo, I. Floriani, A. Buda Randomized trial of neoadjuvant cisplatin (CIS), ifosfamide (IFO) versus CIS, IFO and paclitaxel (PTX) in patients with locally advanced squamous cell cervical cancer (SCCC) Final report on SNAP-01 protocol Proc Am Soc Clin Oncol 22 2003 455 (abstr 1827)
23. R. Kitagawa, N. Katsumata, Y. Yamanaka Phase II trial of paclitaxel (T) and carboplatin (C) in patients with recurrent or metastatic cervical carcinoma Proc Am Soc Clin Oncol 23 2004 459 (abstr 5048)
24. J.E. Sardi, C.E. Sananes, A.A. Giaroli Neoadjuvant chemotherapy in cervical carcinoma stage IIB A randomized controlled trial Int J Gynecol Cancer 8 1998 441 450
25. P. Benedetti-Panici, S. Greggi, A. Colombo Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer Results from the Italian Multicenter Randomized Study J Clin Oncol 20 2002 179 188
26. N. Columbo, A. Gabriele, A. Lissoni Neoadjuvant chemotherapy (NACT) in locally advanced uterine cervical cancer (LAUCC) Correlation between pathological response and survival Proc Am Soc Clin Oncol 17 1998 352 (abstr 1359)
27. W.P. McGuire, W.J. Hoskins, M.F. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
28. R.F. Ozols, B.N. Bundy, B.E. Greer Paclitaxel and carboplatin compared to paclitaxel and cisplatin in patients with optimally resected stage III ovarian cancer A Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
29. F.M. Muggia, P.S. Braly, M.F. Brady Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer A Gynecologic Oncology Group study J Clin Oncol 18 2000 106 115
30. The International Collaborative Ovarian Neoplasm (ICON) Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer The ICON3 randomised trial Lancet 360 2002 505 515
31. M.A. Bookman, W.P. McGuire, D. Kilpatrick Carboplatin and paclitaxel in ovarian carcinoma A phase I study of the Gynecologic Oncology Group J Clin Oncol 14 1996 1895 1902
32. J.B. Vermorken, W.W. ten Bokkel Huinink, E.A. Eisenhauer Advanced ovarian cancer. Carboplatin vs cisplatin Ann Oncol 4 1993 S41 S48
33. R.F. Ozols, B.N. Bundy, B.E. Greer Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in optimal stage III patients with ovarian cancer A Gynecologic Oncology Group Trial (GOG 158) J Clin Oncol 21 2003 1 7
34. J.P. Neijt, S.A. Engelholm, M.K. Tuxen Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer J Clin Oncol 18 2000 3084 3092
35. A. du Bois, H.J. Lück, W. Meier Cisplatin/paclitaxel vs. carboplatin/paclitaxel in ovarian cancer Update of an Arbeitsgemeinschaft Gynäkologie (AGO) Study Group Trial Proc Am Soc Clin Oncol 18 1999 356a (abstr 1374)
36. G. Samimi, D. Fink, N.M. Varki Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy Clin Cancer Res 6 2000 1415 1421
37. S. Faivre, S. Kalla, E. Cvitkovic Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma An investigator- originated compassionate-use experience Ann Oncol 10 1999 1125 1128
38. G. Deplanque, A. Goupil, M. Fabbro Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) as first-line chemotherapy for patients (pts) with advanced ovarian cancer (AOC) Preliminary results Proc Am Soc Clin Oncol 23 2004 466 (abstr 5075)
39. P. Viens, T. Petit, A. Yovine Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) in platinum + taxanes sensitive advanced ovarian cancer (AOC) patients Final results Proc Am Soc Clin Oncol 23 2004 453 (abstr 5023)
40. E.K. Rowinsky, S.H. Kaufmann, S.D. Baker Sequences of topotecan and cisplatin Phase I, pharmacologic, and in vitro studies to examine sequence dependence J Clin Oncol 14 1996 3074 3084
41. J. Pfisterer, M. Plante, I. Vergote Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG Proc Am Soc Clin Oncol 23 2004 449 (abstr 5005)
42. C.R. Underhill, F.X. Parnis, M.S. Highley Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer Anticancer Drugs 12 2001 647 652
43. M.J. Piccart, J.A. Green, A.J. Lacave Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group J Clin Oncol 18 2000 1193 1202
44. K. Chrystal, C.B. Steer, K.A. Cheong Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with advanced epithelial ovarian cancer. A phase II trial of sequential doublets. (GO-FIRST) Proc Am Soc Clin Oncol 23 2004 456 (abstr 5034)
45. D.R. Spriggs, M. Brady, S. Rubin A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer (GOG162) Proc Am Soc Clin Oncol 23 2004 449 (abstr 5004)
46. A. Du Bois, M. Combe, J. Rochon Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB-IV. An AGO-GINECO Intergroup phase III trial Proc Am Soc Clin Oncol 24 2004 449 (late breaker; abstr 5007)
47. M.A. Bookman Developmental chemotherapy and management of recurrent ovarian cancer J Clin Oncol 21 2003 149s 167s
48. P. Sabbatini, M. Hensley, C. Aghajanian Phase I trials of surface antigen vaccines in patients (pts) with epithelial ovarian cancer (EOC) Defining a patient cohort Proc Am Soc Clin Oncol 20 2001 210a (abstr 838)
49. M.E. Gore, I. Fryatt, E. Wiltshaw Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol Oncol 36 1990 207 211
50. M. Markman, R. Rothman, T. Hakes Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 1991 389 393
51. M.M. Leitao Jr, A. Hummer, D.S. Dizon Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy Gynecol Oncol 91 2003 123 129
52. E. Pujade-Lauraine, D. Paraiso, F. Joly Is there a role for platinum in the treatment of patients with "platinum-resistant" relapsed advanced ovarian cancer (AOC)? A GINECO study Proc Am Soc Clin Oncol 22 2003 451 (abstr 1811)
53. V. Hess, P. A'Hern, M.E. Gore Relative platinum-resistance of mucinous carcinoma of the ovary Proc Am Soc Clin Oncol 22 2003 447 (abstr 1796)
54. T. Enomoto, C. Kuragaki, M. Yamasaki Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 22 2003 447 (abstr 1797)
55. ICON and AGO Collaborators J.A. Ledermann Randomised trial of paclitaxel in combination with platinum chemotherapy versus platinum-based chemotherapy in the treatment of relapsed ovarian cancer (ICON4 / OVAR 2.2) Proc Am Soc Clin Oncol 22 2003 446 (abstr 1794)
56. E.L. Jones, L.R. Prosnitz, T.V. Samulski Intraperitoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma Proc Am Soc Clin Oncol 23 2004 457 (abstr 5038)
57. K. Fujiwara, S. Suzuki, H. Ishikawa Toxicity of intraperitoneal (IP) carboplatin and intravenous (IV) paclitaxel chemotherapy Proc Am Soc Clin Oncol 22 2003 482 (abstr 1938)
58. D. Armstrong, B. Bundy, R. Baergen Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC) A Gynecologic Oncology Group trial (GOG 172) Proc Am Soc Clin Oncol 21 2002 201a (abstr 803)
59. P.G. Rose, K. Mossbruger, N. Fusco Gemcitabine reverses cisplatin resistance demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma Gynecol Oncol 88 2003 17 21
60. N. Dohollou, B. Weber, J.-F. Geay Gemcitabine (GE) and oxaliplatin (OX) in patients with recurrent advanced ovarian cancer in early progression (<6 months) (AOCEP) A GINECO phase II trial Proc Am Soc Clin Oncol 22 2003 451 (abstr 1813)